Introduction: The use of a bronchial genomic classifier has been shown to improve the diagnostic accuracy of bronchoscopy for suspected lung cancer by identifying patients who may be more suitable for radiographic surveillance as opposed to invasive procedures. Our objective was to assess the cost-effectiveness of bronchoscopy plus a genomic classifier versus bronchoscopy alone in the diagnostic workup of patients at intermediate risk for lung cancer.
Introduction
Bronchoscopy is a commonly used first diagnostic procedure in the work-up of patients with pulmonary lesions suspected to be lung cancer. 1 Its relatively frequent use is based, in part, on its lower procedure risk profile compared with that of transthoracic needle aspiration (TTNA) or surgical lung biopsy. 2 Prior data suggest that a substantial percentage of patients with benign lesions undergo invasive procedures subsequent to inconclusive findings in the initial bronchoscopy, exposing them to procedural risks and discomfort and creating additional cost burden to the health care system. 3 Recently, findings from Airway Epithelial Gene Expression in the Diagnosis of Lung Cancer (AEGIS)-1 and AEGIS-2, two multicenter prospective substudies enrolling current or former smokers undergoing bronchoscopy for suspected lung cancer, have shown that a negative classifier score in patients with an intermediate (10%-60%) pretest probability of lung cancer and a nondiagnostic bronchoscopy result decreases the posttest probability of lung cancer to less than 9%, supporting a more conservative diagnostic approach. 4 Our primary objective in this study was to evaluate the cost-effectiveness of the use of bronchoscopy plus the classifier versus bronchoscopy alone from a U.S. third-party payer perspective based on the findings of the AEGIS intermediate-risk cohort. Our secondary objective was to estimate the impact of classifier use on the number of invasive procedures performed through 2 years of follow-up.
Methods
Our analysis considered the diagnostic work-up of intermediate-risk patients over a 2-year time horizon, using population and test performance characteristics observed in the AEGIS 1 and 2 studies to assess diagnostic outcomes during the index diagnostic procedure. This information provided the initial input to a state transition (Markov) model used to project, for each strategy, the further diagnostic work-up and invasive and surgical procedures. This model type was chosen because state transition models make it possible to follow subpopulations of patients in different disease states over time and assign different transition probabilities and rewards that can be assessed in uncertainty analyses. A follow-up time horizon of 2 years was chosen on the basis of current clinical guidelines, which recommend ensuring radiographic stability for a period of up to 2 years.
For each of the two strategies, we computed the estimated numbers of invasive procedures including surgery over the 2-year time horizon, the total (technical and professional) costs of noninvasive and invasive follow-up, and gains in health-related quality of life, as measured through projected gains in quality-adjusted life-years (QALYs). A schematic representation of the model structure is shown in Figure 1 ; further details about the model framework are provided in the Supplementary Data.
The primary outcome measure of the analysis was the incremental cost-effectiveness ratio (ICER), defined as the incremental direct costs of the classifier strategy divided by the incremental health benefits measured as QALYs and taking into account gains in both survival and health-related quality of life. 5 The ICER is the primary metric used in health economic analyses to assess the value of an intervention. 6 Strategies associated with ICER values up to $50,000 per QALY gained are considered "good value" investments for health care systems in the U.S. setting, and ICERs up to $150,000 per QALY are considered to be of value. [7] [8] [9] The secondary outcome measure was the estimated number of invasive procedures performed under each strategy, measured on the basis of model-projected procedure incidence at 1 month and 24 months after the index procedure. The analysis took the perspective of third-party payers in the U.S. health care system, considering a mix of Medicare and privately insured patients based on the payer mix obtained from a recent claims data analysis of bronchoscopies performed in a cohort representative of the AEGIS cohort and in line with the target population for the test. Costs to payers over the 2-year period were based on detailed accounting of all procedure costs, including costs associated with the treatment of adverse events. In line with current guidelines for health economic analysis, costs and health outcomes were discounted at 3% per year. 10 The AEGIS study and its findings have been presented elsewhere. 4 A total of 639 patients were included in AEGIS-1 and AEGIS-2 substudies across the 28 participating centers. In patients in whom the study bronchoscopy result was nondiagnostic, the bronchial genomic classifier (Percepta [Veracyte, Inc., South San Francisco, CA]) was measured in a sample collected from brushing of the mainstem bronchus to assess the probability of lung cancer. Although the AEGIS population included patients at low, intermediate, and high risk of suspected lung cancer, the current study uses input from the intermediate-risk cohort of the AEGIS study only, which is in line with the primary expected use of the test. Thus, test performance observed in the subgroup of 101 AEGIS patients who had an intermediate pretest probability of cancer formed the basis for the current analysis (Table 1 4,11-26 ). Of these patients, 41% were ultimately found to have a cancerous lesion. Assumptions about the diagnostic performance of imaging follow-up and subsequent invasive procedures were derived from the published literature on the basis of cohorts that resembled the characteristics of the AEGIS cohort as closely as possible.
In the AEGIS intermediate-risk cohort, bronchoscopy alone was found to have a mean sensitivity of 41% and a specificity of 100%. The classifier was found to have a negative predictive value of 91% (95% confidence interval: 75-98) among patients with a nondiagnostic bronchoscopic examination result. 4 In combination, bronchoscopy plus the classifier were found to have a combined sensitivity of 93% and specificity of 48%. A second bronchoscopy performed after the index bronchoscopy was assumed to have the same diagnostic performance as the prior bronchoscopy. On the basis of a recent study, TTNA was assumed to have a sensitivity of 89.8% and specificity of 100%. 16, 27 Video-assisted thoracic surgery (VATS) and thoracotomy were assumed to always lead to a definitive and correct diagnosis. Noninvasive imaging follow-up using computed tomography (CT) was assumed to have a sensitivity of 96.5%. 11 Because repeat imaging cycles can be assumed to be associated with gradually decreasing false-positive rates over time, and thus with an increase in specificity, our specificity estimate was time dependent in the model and increased from 92% at time of the index bronchoscopy to 99% at 9 months (i.e., in the third sequential CT scan performed as part of noninvasive follow-up). For positron emission tomography (PET), we assumed an 84% sensitivity and 76% specificity. 11, 14, 15 We assumed that noninvasive follow-up was performed in 93% of cases with CT examination as opposed to PET.
On the basis of data from the AEGIS intermediate-risk cohort, we assumed that 57% of patients with an inconclusive bronchoscopy result or bronchoscopy plus classifier result would be followed up invasively-with a second bronchoscopy, a TTNA procedure, or a surgical biopsy through VATS or thoracotomy. 17 On the basis of the AEGIS data, 41% of invasive follow-up procedures were assumed to be performed as surgical procedures, with 57.5% of these by VATS as opposed to thoracotomy. Thirty-six percent of invasive procedures involved a second bronchoscopy. The remaining 23% of patients underwent TTNA. All diagnostic findings for lung cancer on invasive follow-up were assumed to lead to a surgical procedure in which cancerous lesions were removed as appropriate. A diagnosis of lung cancer during VATS or thoracotomy would lead to removal of the lesion in the same procedure, whereas diagnosis achieved at bronchoscopy or TTNA was treated with a subsequent surgical procedure.
Costs in 2016 U.S. dollars were considered from the third-party payer perspective and assumed a payer mix based on a recent claims data analysis of bronchoscopic procedures performed for suspected cancer. The cost of the Percepta classifier was assumed to be $3200 on the basis of current pricing and cost ranges of reimbursed genomic markers for other indications. When costs were available from earlier years, we used the medical cost price index to compound. Detailed data and assumptions can be found in Table 1 and in the Supplementary Data.
Mortality was derived from sex-stratified life tables for the United States and was adjusted for patients with malignant lesions. Utility estimates were derived from the published literature.
11 Procedure-related disutility was incorporated on the basis of a QALY decrement defined by a procedure-specific temporary reduction in utility (see Table 1 and Supplementary Data).
Comprehensive one-way and multiway sensitivity analyses were conducted to evaluate the effects of parameter uncertainty, including variations in test performance, decision making in diagnostic work-up, and test and procedure costs. The parameter ranges were derived from the AEGIS results, published data, and expert opinion where applicable. In addition, several scenario analyses were computed, including scenarios for a sole commercial or Medicare perspective and an assumed shorter analysis horizon of only 1 year.
Results
Our model found a reduction of invasive procedures at 1 month by 28.0% (0.46 versus 0.64 procedures), and surgical procedures-as a subset of invasive proceduresby 19.4% (0.33 versus 0.41). At 2 years, invasive procedures were reduced by 18.3% (0.73 versus 0.90), and surgical procedures by 11.5% (0.52 versus 0.58) (Fig. 2) . Projected cohort life-years over 2 years were 1.908 in the classifier strategy compared with 1.906 (þ0.002) in the bronchoscopy-only strategy. The discounted QALYs were 1.512 versus 1.509 QALYs, for a gain of 0.003 QALYs. Total discounted costs at 2 years were $27,221 for the classifier strategy, and $27,183 for bronchoscopy only (a difference of $38). As a result, the ICER at 2 years was $15,052 per QALY gained ( Table 2) . Table 3 provides an overview of the most relevant sensitivity results, including the discounted ICERs and discounted cost and QALY differences for classifier versus bronchoscopy only at 2 years. Decreasing the sensitivity of bronchoscopy to the 25th percentile observed in AEGIS led to an ICER of around $60,000 per QALY gained, whereas increasing it to the 75th percentile led to dominance of the classifier strategy, for a savings of $92. Decreasing the combined specificity of bronchoscopy and classifier to the 25th percentile value of 40% led to an ICER of $214,000 per QALY gained, whereas increasing it to the 75th percentile (57%) made classifier use the dominant strategy, at a projected savings of $448.
Increasing the probability of invasive follow-up after a nondiagnostic bronchoscopy result had a distinct effect on cost-effectiveness. When a value of 61% was assumed instead of the 57% assumed in the base case, 17 the classifier strategy was dominant, at a total savings of $145. Decreasing the probability to 53% resulted in an increase of the ICER to around $94,000 per QALY gained. Assuming different utilization of thoracoscopy in surgical biopsy and treatment also had a distinct impact on cost-effectiveness. Reducing the 57.5% thoracoscopy estimate observed in AEGIS to 26% (as has been reported in the American College of Surgeons' National Surgical Quality Improvement Program data 18 ) on the basis of a total of 2353 cases reflecting a cross section of U.S. hospitals and surgeons resulted in savings of $191 and made classifier use the dominant strategy. Conversely, a higher thoracoscopy estimate of 61% based on a total of 27,844 cases documented in the Society of Thoracic Surgeons General Thoracic Surgery Database 17 led to a limited increase in the ICER to a value of around $25,000 per QALY gained. A combined specificity of bronchoscopy and classifier of 40%, reflecting the lower bound specificity in AEGIS, was projected to lead to a $458 cost increase, with a resulting ICER of $214,052, whereas the upper bound specificity of 57% was projected to make classifier use the dominant strategy, at a cost savings of $448.
For variations in other parameters, the costeffectiveness projections were found to be widely robust across a wide range of assumptions, including changes in assumptions about procedure-related disutility and diagnostic performance of bronchoscopy and imaging follow-up.
Reducing the time frame of the analysis to a followup period of 1 year led to an ICER of $11,358 per QALY gained, on the basis of a projected cost increase of $19 at a concurrent QALY gain of 0.002. Increasing the share of commercial payers in the payer mix to values of 56% and higher made classifier use dominant and resulted in overall savings. Reducing the share of commercial payers to 30% led to a cost increase of $304 and a resulting ICER of $119,368 per QALY gained.
Conclusions
Our health economic analysis uses a decision-analytic Markov model to assess how the classifier-related increases in test performance affect the clinical work-up of these intermediate-risk patients and, as a result, affects patient outcomes and costs to payers. Our projections suggest that use of the classifier can be expected to meaningfully reduce invasive and surgical procedures over a 2-year follow-up horizon, leading to a slight increase in patients' projected QALYs. The added classifier cost of $3200 is almost completely absorbed by net reductions in total procedure costs, rendering use of the classifier a cost-effective strategy at an ICER of around $15,000 per QALY, which is well below the commonly accepted willingness-to-pay thresholds of $50,000 to $150,000 per QALY gained.
This cost-effectiveness profile is sensitive to a number of parameters, though, including diagnostic performance of bronchoscopy and the classifier, the payer mix, and the frequency of thoracotomy being used in surgical follow-up as compared with VATS. The most notable variation in cost-effectiveness outcome was observed for low combined specificity of bronchoscopy and classifier, with a projected ICER of $214,000, a value above the previously referenced threshold of $150,000 per QALY gained. Our model did not account for the increasing use of radial endobronchial ultrasound or navigational bronchoscopy, both of which would add to the cost of the procedure and might increase the diagnostic yield of bronchoscopy. 28, 29 A second important point is the physician and patient preferences in the case of an inconclusive bronchoscopy result. As would be expected, the classifier's health economic profile was found to become increasingly more favorable as the percentage of invasive follow-up was assumed to be higher than the estimate determined in the recent PIONEER study. 17 A reduction in this parameter decreased cost-effectiveness. Ongoing research studies about physician and patient preferences and current decision making will provide useful additional data to underpin and validate our current findings.
As shown in our sensitivity analysis, a third key parameter is the percentage of thoracoscopy versus thoracotomy use in surgical biopsies and applicable lesion removal. This parameter affects cost-effectiveness primarily on the basis of the higher costs of a thoracotomy procedure (i.e., the observed reductions in surgical procedure use have a higher impact to counter the upfront Bronch, bronchoscopy; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
cost of the classifier). The second impact results from differences in procedure-related mortality and impact on quality of life, which affect the projected QALYs.
A fourth observation in our study is the impact that procedure costs have on the value proposition of the classifier test, with the cost-effectiveness of classifier use further improving with increasing commercial payer share and rapidly reaching dominance (i.e., overall cost savings at improved patient outcomes). Conversely, an increase in Medicare patients in the payer mix led to a gradual increase in the ICER.
The results of this study align with prior costeffectiveness findings for a number of well-accepted and currently reimbursed genetic classifiers, including molecular testing for thyroid nodules, for which favorable health economic profiles were found. [30] [31] [32] Our analysis is subject to several limitations. First, the AEGIS studies focused primarily on the evaluation of the test characteristics during the index bronchoscopy. Although diagnostic data were collected through 12 months, information from AEGIS was not available through the 2-year time frame modeled in our study. However, all patients included in the AEGIS analysis reached a definitive diagnosis within the 12-month AEGIS study time frame. Second, although our analysis relies on the key test performance data from AEGIS, it builds on a decision-analytic model structure for follow-up that aimed to resemble current guidelineinformed practice in follow-up and decision making. As such, our model resembles pathways that can reasonably be expected to reflect reality in current clinical practice but might not resemble the full spectrum of pathways that might be observed in practice. However, this is a typical and widely accepted limitation of any decision-analytic model. Similarly, although our findings were shown to be robust over various scenarios and ranges, they are derived from a specific population (the AEGIS-1 and AEGIS-2 cohorts) that may not reflect the full spectrum of potential patient characteristics. Third, and related to the last point, our model needed to build on literature-based estimates of test performance of imaging and invasive procedures, including CT, PET and TTNA. Test characteristics of these procedures can depend heavily on the underlying population, geography, lesion characteristic, local expertise, and timing of procedures. We carefully reviewed the literature and aimed to identify test performance from studies with populations that were reasonably close to the AEGIS intermediate-risk population, and more importantly, that reflected the characteristics of the expected target population of commercial use of the classifier. Evaluation of the effect of changes in test characteristics was performed in sensitivity analyses. Further, as test characteristics influence the total number of invasive and surgical procedures over given follow-up time frames, we were able to evaluate our model-projected data against the AEGIS procedure counts reported at 12 months and found them to be reasonably close to our model projections.
Fourth, no cost data were collected in AEGIS. As such, we needed to develop estimates based on procedure reimbursement and literature-informed estimates of complication rates for some procedures. However, we performed a detailed chart review of all 41 surgical patients in the AEGIS intermediate-risk cohort to assess the specific procedures and complications and the associated physician coding assumptions, and we used an aggregate average of the actual site-specific Medicare reimbursement amounts for inpatient procedures at each of the 23 U.S. sites in AEGIS (see the Supplementary Data for detail). Our estimation of private payer reimbursement estimates was based on the determined Medicare amounts and commonly used multipliers to determine commercial reimbursement amounts for professional fees and inpatient and outpatient provider fees.
Fifth, health-related quality of life was based on previous studies of lung cancer diagnosis and lung cancer treatment, and on estimations of procedure-related QALY decrements. However, our assumed decrements for thoracotomy and thoracoscopy are in line with most recent data evaluating health-related quality of life in patients undergoing these procedures, and our assumptions about other procedures, including TTNA and bronchoscopy, compare reasonably against the higher decrements assumed for surgical biopsy. In addition, we tested the effect of variation in these parameters in sensitivity analyses, which showed only minimal impact on the ICER. Although some surgical procedures are solely diagnostic (i.e., a VATS wedge resection), it should be recognized that surgical biopsy can be both diagnostic and therapeutic and as such, some of the reduction in QALYs should be expected with a therapeutic procedure over the purely diagnostic capabilities of bronchoscopy and TTNA. Finally, our model assumed no impact of time to diagnosis of malignant lesions on ultimate patient outcome. However, this seems reasonable given the frequency of CT surveillance, the relatively short time frame between index bronchoscopy and a definitive diagnosis, and the general characteristics of lesions that can be expected in the type of cohort studied. As shown in the AEGIS validation cohort, all malignant lesions were diagnosed within a year, with most being diagnosed in the first few months. Our model projections suggest that any delays to diagnosis in the classifier strategy-as compared with bronchoscopy only-can be expected to be minimal in patients with malignant disease and to not have any impact on long-term patient survival, quality of life, or future procedures. This further justifies our use of a 2-year analysis horizon for this study in lieu of a lifetime horizon.
In summary, our findings suggest that use of a bronchial genomic classifier in an intermediate-risk population during index bronchoscopy can lead to meaningful reductions in invasive follow-up procedures. The related procedure cost savings and procedure risk reduction largely compensate for the cost of the classifier and lead to a favorable health economic profile across a wide range of assumptions.
